XM does not provide services to residents of the United States of America.
S
S

Stryker

Technical Summary

IndicatorValueTrend
IndicatorValueTrend
IndicatorValueTrend
IndicatorS3S2S1PR1R2R3

News

Medical device makers fall after J&J's medtech unit misses sales estimates

BUZZ-Medical device makers fall after J&J's medtech unit misses sales estimates ** Shares of medical device makers fall between 1% and 3% after Johnson & Johnson's JNJ.N medical devices unit reports Q1 sales of $7.82 bln, missing Wall Street estimates of $7.88 bln, per LSEG data ** Stryker SYK.N down 1%, Zimmer Biomet ZBH.N down 1.2%, Medtronic MDT
A
B
S
Z

J&J's medical device sales fall short, cancer drugs seen growing

UPDATE 5-J&J's medical device sales fall short, cancer drugs seen growing Recasts with focus on medical device sales miss, Adds investor call details in paragraphs 8-10 and 17, updates shares By Patrick Wingrove and Bhanvi Satija April 16 (Reuters) - Johnson & Johnson's JNJ.N first-quarter revenue missed Wall Street estimates for medical devices on Tuesday and sales of its blockbuster psoriasis drug Stelara came in lower than expected as the company prepares for its loss of exclusivity in the U.
S
Z

Truist bets on a 'beat & raise' Q1 for some med-tech players

BUZZ-Truist bets on a 'beat & raise' Q1 for some med-tech players ** Brokerage Truist Securities expects Q1 results beat and forecast raises for medical device makers Boston Scientific Corp BSX.N and Intuitive Surgical ISRG.O , among others ** Medical device makers have been benefitting in recent quarters due to a resurgence in demand for joint rep
S
Z

Activist Politan seeks more seats on Masimo's board to boost presence

UPDATE 4-Activist Politan seeks more seats on Masimo's board to boost presence Adds company statement in paragraph 6 March 25 (Reuters) - Politan Capital Management has nominated two directors to the board of Masimo Corp MASI.O , the activist shareholder said on Monday, marking the possible start of a second proxy battle after winning two seats last year at the medical device firm.
A
A
S

Stryker Completes Acquisition Of Serf Sas

BRIEF-Stryker Completes Acquisition Of Serf Sas March 21 (Reuters) - Stryker Corp SYK.N : STRYKER COMPLETES ACQUISITION OF SERF SAS Source text for Eikon: ID:nPn642YGqa Further company coverage: SYK.N
S

Conditions

Popular Assets

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.